Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Antiestrogen Interaction with Estrogen Receptors and Additional Antiestrogen Binding sites in Human Breast Cancer MCF-7 Cells

  • Published : 1997.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

To gain further insight into the mechanism of action of antiestrogens, we examined the interaction of antiestrogen with the estrogen receptor system and with estrogen- noncompetable antiestrogen binding sites. In addition to binding directly to the estrogen receptor, antiestrogens can be found associated with binding sites that are distinct from the estrogen receptor. In contrast to the restriction of estrogen receptors to estrogen target cells, such as those of uterus and mammary glands, antiestrogen binding sites are present in equal amounts in estrogen receptor-positive and -negative human breast cancer cell lines, such as MCF-7, T47D, and MDA-MB-231 that differ markedly in their sensitivity to antiestrogens. In order to gain greater insight into the role of these antiestrogen binding sites in the action of antiestrogens, we have examined the biopotency of different antiestrogens for the antiestrogen binding sites and that is CI628 > tamoxifen > trans-hydroxy tamoxifen > CI628M > H1285 > LY117018. This order of affinities does not parallel the affinity of these compounds for the estrogen receptor nor the potency of these compounds as antiestrogens. Indeed, compounds with high affinity for the estrogen receptor and greatest antiestrogenic potency have low affinities for these antiestrogen binding sites. Antiestrogenic potency correlates best with estrogen receptor affinity and not with affinity for antiestrogen binding sites. In summary, our findings suggested that interaction with the estrogen receptor is most likely the mechanism through which antiestrogens evoke their growth inhibitory effects.

Keywords

References

  1. Methods Enzymol. v.31 Non-destructive separation of rat liver rough microsomes into ribosomal and membranous components Adelman,M.R.;Blobel,G.;Sabatini,D.D.
  2. Recent Results Cancer Res. v.127 What did we learn from the results of the international overview about the effects of endocrine therapy? Bonadonna,G.
  3. Cancer. Res v.46 Use of two MCF-7 cell variants to evaluate the growth regulatory potential of trans-tamoxifen-induced products Davidson,N.E.;Bronzert,D.A.;Chambon,P.;Gelmann,E.P.;Lippman,M.E.
  4. J. Steroid. Biochem. Mol. Biol. v.37 Regulation of proliferation, invasion, and growth factor synthesis in breast cancer by steroids Dickson,R.B.;Thompson,E.W.;Lippman,M.E.
  5. Cancer. Res. v.42 Effects of transtamoxifens and antitrans-tamoxifens on trans-tamoxifen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells Eckert,R.L.;Katzellenbogen,B.S.
  6. Proc. Natl. Acad. Sci. USA v.80 Physicochemical and genetic evidence for specific antiestrogen binding sites Faye,J.C.;Jozan,S.;Redeuilth,G.;Baulieu,E.E.;Bayard,F.
  7. Recent Results Cancer Res. v.127 Adjuvant systemictherapy; overview Henderson,I.C.
  8. J. Biol. Chem. v.253 Nuclear mechanism of estrogen receptor action Horwitz,K.B.;McGuire,W.L.
  9. Breast. Cancer. Res. and Treatment v.5 Antitrans-tamoxifen action in breast cancer cells Katzellenbogen,B.S.;Miller,M.A.;Mullick,A.;Sheen,Y.Y.
  10. Cancer. Res. v.44 Bioactivity estrogen receptor interactions and plasmin activator inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 breast cancer cells Katzellenbogen,B.S.;Norman,M.J.;Eckert,R.L.;Peltz,S.W.;Mangel,W.F.
  11. Nature v.307 Monoclonal antibodies localize trans-tamoxifen receptor in nuclei of target cells King,W.J.;Green,G.L.
  12. Endocrine-dependent Tumors Regulation of growth inhibitory polypeptides in human breast cancer Knabbe,C.;Voigt,K.D.(ed.);Knabbe,C.(ed.)
  13. Arch. Pharm. Res. v.20 Estrogen modulation of breast cancer cell growth Lee,H.O.;Sheen,Y.Y.
  14. Adv. Intern. Med. v.24 Steroid receptor sites in cancer therapy McGuire,W.L.
  15. Cancer. Res. v.44 antiestrogen binding in antiestrogen growth resistant estrogen responsive clonal variants of MCF-7 huamn breast cancer cell Miller,M.A.;Lippman,M.E.;Katnellenbogen,B.S.
  16. Adv. Cancer. Res v.17 Mammary neoplasia in mice Nandi,S.;McGrath,C.M.
  17. Drug. Metab. and Disposition v.12 Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen Ruenitz,P.C.;Bagley,J.R.;Pope,C.W.
  18. Ann. NY Acad. Sci. v.51 The attractions of protein for small molecule and ions Schatchard,G.
  19. Endocrinology v.117 An evaluation of the role of antiestrogen binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyenthyl diethylamine, a compound lacking affinity for estrogen receptor Sheen,Y.Y.;David,M.S.;Katzellenbogen,B.S.
  20. Endocrinology v.112 Antiestrogen binding sites are distinct from estrogen receptor Sudo,K.;Mondma,F.J.;Katzellenbogen,B.S.
  21. Nature v.288 High affinity antiestrogen binding sites distinct from the estrogen receptor Sutherland, R.L.;Foo,M.S.;Green,M.D.;Waybourne,A.M.;Krozowski,Z.S.
  22. Biochem. Biophys. Res. Commun. v.120 Hifh affinity specific antiestrogen binding sites are concentrated in rough endoplasmic microsomal membranes of rat liver Watts,C.K.W.;Sutherland,R.L.